Abstract
Many types of oncolytic viruses, wild-type virus, attenuated viruses and genetically-modified viruses, have been developed as an innovative cancer therapy. The strategies, nature, and technologies of oncolytic virus products are different from the conventional gene therapy products or cancer therapy products. From the regulatory aspects to ensure the safety, efficacy and quality of oncolytic viruses, there are several major points during the development, manufacturing, characterization, non-clinical study and clinical study of oncolytic viruses. The major issues include 1) virus design (wild-type, attenuated, and genetically engineered strains), 2) poof of concept in development of oncolytic virus products, 3) selectivity of oncolytic virus replication and targeting to cancer cells, 4) relevant animal models in non-clinical studies, 5) clinical safety, 6) evaluation of virus shedding. Until now, the accumulation of the information about oncolytic viruses is not enough, it may require the unique approach to ensure the safety and the development of new technology to characterize oncolytic viruses.
Keywords: Gene therapy, cancer therapy, replicating virus
Current Cancer Drug Targets
Title: Regulatory Aspects of Oncolytic Virus Products
Volume: 7 Issue: 2
Author(s): Teruhide Yamaguchi and Eriko Uchida
Affiliation:
Keywords: Gene therapy, cancer therapy, replicating virus
Abstract: Many types of oncolytic viruses, wild-type virus, attenuated viruses and genetically-modified viruses, have been developed as an innovative cancer therapy. The strategies, nature, and technologies of oncolytic virus products are different from the conventional gene therapy products or cancer therapy products. From the regulatory aspects to ensure the safety, efficacy and quality of oncolytic viruses, there are several major points during the development, manufacturing, characterization, non-clinical study and clinical study of oncolytic viruses. The major issues include 1) virus design (wild-type, attenuated, and genetically engineered strains), 2) poof of concept in development of oncolytic virus products, 3) selectivity of oncolytic virus replication and targeting to cancer cells, 4) relevant animal models in non-clinical studies, 5) clinical safety, 6) evaluation of virus shedding. Until now, the accumulation of the information about oncolytic viruses is not enough, it may require the unique approach to ensure the safety and the development of new technology to characterize oncolytic viruses.
Export Options
About this article
Cite this article as:
Yamaguchi Teruhide and Uchida Eriko, Regulatory Aspects of Oncolytic Virus Products, Current Cancer Drug Targets 2007; 7 (2) . https://dx.doi.org/10.2174/156800907780058790
DOI https://dx.doi.org/10.2174/156800907780058790 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs in Breast Cancer Therapy
Current Pharmaceutical Design Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis
Medicinal Chemistry In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry Is there a Possible Single Mediator in Modulating Neuroendocrine–thymus Interaction in Ageing?
Current Aging Science Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Current Pharmaceutical Design PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Current Cancer Drug Targets Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry PET Imaging for Gene & Cell Therapy
Current Gene Therapy EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Editorial [Hot topic: Target Therapy of Bone Metastases and Tumours (Guest Editors: M. Caraglia and D. Santini)]
Current Cancer Drug Targets Viral Vectors in Cancer Immunotherapy: Which Vector for Which Strategy?
Current Gene Therapy Modulation of Calcium Signaling in Glioblastoma Multiforme: A Therapeutic Promise for Natural Products
Mini-Reviews in Medicinal Chemistry Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel
Anti-Cancer Agents in Medicinal Chemistry Kinase Inhibitors in Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science Modulation of Interleukin-10 Production by Therapeutic Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents